Publication Summary
This study by Jung et al. examines matrix metalloproteinases (MMPs) as biomarkers and therapeutic targets in facioscapulohumeral muscular dystrophy (FSHD). The researchers found that MMP expression strongly correlates with disease severity in FSHD patients and is elevated even in early, uninflamed muscle tissue. Using the iDUX4 mouse model of FSHD, they identified fibroadipogenic progenitors (FAPs) and macrophages as the primary sources of MMPs, particularly MMP2, MMP14, and MMP19, during muscle degeneration. Treatment with batimastat, a pan-MMP inhibitor, reduced inflammation, fibrosis, FAP infiltration, and macrophage accumulation while improving muscle structure in the mouse model. The findings suggest that MMPs drive muscle pathology in FSHD and that MMP inhibitors could serve as a DUX4-independent therapeutic approach to mitigate disease progression.
How was Levitation Technology Used in the Paper?
LeviCell EOS served as a critical sample cleanup step to ensure high-quality, viable cells were used for the downstream single-cell RNA sequencing analysis, which identified FAPs and macrophages as the primary sources of MMPs in FSHD muscle.
